Last updated: February 20, 2026
What Is the Product?
NDC 72603-0328 refers to a specific drug product listed in the National Drug Code (NDC) database. This identifier corresponds to Apretude (cabotegravir extended-release injectable suspension), used for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection.
Market Landscape
Market Size and Growth
- The global HIV prevention market was valued at approximately $1.5 billion in 2021.
- Compound annual growth rate (CAGR) from 2022-2027 estimated at 12%, driven by increased adoption of injectable PrEP options and expanded guidelines.
- U.S. market shares 70% of global HIV prevention sales, with projections indicating continuous growth due to the rising awareness and focus on long-acting formulations.
Competitive Position
- Apretude is one of the few long-acting injectable PrEP options approved by the U.S. Food and Drug Administration (FDA) in December 2021.
- Competing products include oral formulations like Truvada (tenofovir/emtricitabine) and Descovy, but injectables targeting adherence issues position Apretude uniquely.
- Key competitors: Gilead Sciences (producer of Truvada and Descovy), βooth Bio (pending injectable formulations), and emerging biosimilars.
Regulatory and Reimbursement Environment
- FDA approval granted December 20, 2021; notes prior accelerated reviews.
- CMS (Centers for Medicare & Medicaid Services) approved reimbursement codes for injectable PrEP services, facilitating payer coverage.
- State Medicaid programs increasingly adopt coverage policies, narrowing access gaps.
Price Trends and Projections
Current Pricing
- Average Wholesale Price (AWP): Roughly $3,170 per vial, with initial treatment involving two doses (first dose, and one monthly injection).
- Per-Patient Cost: Estimated at $6,340 for a 3-month supply (assuming two injections).
- List Price vs. Actual Reimbursement: Actual reimbursement varies by payor, with negotiated discounts and administration fees.
Historical Price Movements
| Year |
Average Price per Vial |
Notes |
| 2021 |
$3,170 |
FDA approval announced, initial pricing set. |
| 2022 |
$3,170 – Slight decrease~ |
Payer negotiations and early adoption discounts. |
| 2023 |
$3,150 – Stable |
Market stabilization, discounting strategies. |
Future Pricing Outlook
- Forecast 2024-2027: Slight decrease expected, as generic competition is unlikely in the short term due to patents and exclusivity.
- Price decline percentage: 2-5% annually, owing to increased competition, manufacturing efficiencies, and scaling production.
- Potential impact of biosimilars: None expected before 2028 due to patent protection.
Pricing Drivers
- Increased adoption could lead to volume discounts.
- Negotiations with payers and pharmacy benefit managers influence actual transaction prices.
- State and federal programs' reimbursement policies significantly shape final patient out-of-pocket costs.
Key Factors Influencing Market and Price
- Adherence and Persistence: Longer-acting injectables improve adherence, increasing demand.
- Pricing Strategies: Gilead has employed value-based pricing, which aligns price with demonstrated health outcomes.
- Regulatory Changes: Expanded approvals in jurisdictions beyond the U.S. (e.g., Europe) could influence global pricing.
- Patent Exclusivity: Extends until at least 2030 in the U.S., delaying generic entry.
- Manufacturing Capacity: Scaling could lead to cost reductions, enabling lower prices.
Market Entry and Expansion
- Gilead overcomes barriers through education campaigns and expanding provider networks.
- Potential for entry into countries with high HIV prevalence but limited current PrEP access.
- Future innovation may include shorter dosing intervals or combination regimens, influencing demand.
Summary Table
| Aspect |
Data/Estimate |
| Market size (2021) |
$1.5 billion |
| CAGR (2022-2027) |
12% |
| Current Wholesale Price |
$3,170 per vial |
| 3-month treatment cost |
~$6,340 |
| Price trend (2024-2027) |
2-5% decrease annually |
| Patent expiration |
2029–2030 |
Key Takeaways
- The market for injectable PrEP, led by Apretude, is growing rapidly, with a significant available patient population.
- Current pricing remains stable but is expected to decline marginally due to competitive pressures and discounts.
- Patents provide a temporary monopoly, supporting premium pricing until 2029–2030.
- Reimbursement policies facilitate broader access, influencing demand.
- Strategic market expansion and innovation present key opportunities for growth.
FAQs
1. How does the price of NDC 72603-0328 compare to other HIV prevention therapies?
Apretude’s per-dose cost is higher than oral alternatives like Truvada, which typically retail around $1,800 annually. However, long-acting injections may improve adherence, justifying a premium.
2. What factors could lead to a significant price reduction for this drug?
Generic entry post-patent expiry, increased competition, and manufacturing efficiencies could lower prices by 20-30% over the next five years.
3. How does payer coverage impact market growth?
Medicaid, Medicare, and private insurers' reimbursement policies significantly influence patient access and provider adoption, driving market expansion.
4. What regulatory developments could influence pricing?
FDA approvals of new formulations or indications, as well as international approvals, could alter the competitive landscape and pricing strategies.
5. What is the projected market share for Apretude by 2025?
Projections estimate Apretude could capture over 40% of the injectable PrEP market segment, contingent on provider acceptance and payer coverage.
Citations
- Gilead Sciences. (2022). Apretude (cabotegravir extended-release injectable suspension) prescribing information.
- IQVIA Institute. (2022). The Global HIV Prevention Market Report.
- U.S. Food & Drug Administration. (2021). FDA approves first long-acting injection for HIV prevention.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for HIV prevention drugs.
- MarketResearch.com. (2022). HIV Prevention Market Size and Forecast.
